Baricinix 2MG & 4MG (Baricitinib)

Basic Product Information of Baricinix 2MG & 4MG (Baricitinib)

How Baricinix 2MG & 4MG (Baricitinib) Works JAK-STAT Pathway Inhibition

Baricitinib, the active ingredient in Baricinix 2MG & 4MG, is a selective and reversible inhibitor of Janus kinase enzymes JAK1 and JAK2. Janus kinases (JAKs) are intracellular enzymes that transmit signals from the surface of immune cells in response to cytokines and growth factors involved in haematopoiesis, inflammation, and immune function. In autoimmune conditions such as rheumatoid arthritis and atopic dermatitis, these JAK-STAT signalling pathways become chronically overactive, driving sustained inflammation and progressive tissue damage.

Baricitinib works by partially inhibiting JAK1 and JAK2 enzymatic activity with IC50 values of 5.9 nM and 5.7 nM respectively thereby reducing the phosphorylation and activation of Signal Transducers and Activators of Transcription (STATs). By blocking this cascade, Baricinix interrupts the inflammatory signals responsible for joint pain, swelling, stiffness, and tissue destruction in rheumatoid arthritis, and skin inflammation in atopic dermatitis. Baricitinib is selective for JAK1 and JAK2 over JAK3 and TYK2 at therapeutic concentrations, contributing to its focused mechanism and manageable tolerability profile.

Unlike biologic DMARDs administered by subcutaneous or intravenous injection, Baricinix is a convenient once-daily oral film-coated tablet. This oral route of administration offers patients a practical and well-tolerated alternative to injectable therapies without compromising therapeutic efficacy. In the landmark RA-BEAM trial, Baricitinib demonstrated superiority over adalimumab and placebo in ACR20 response rates at Week 12, establishing its clinical value as a front-line advanced therapy option for rheumatoid arthritis. Physicians and patients seeking a broader view of oncology and specialty medicines available through Mediaid Pharmacy can review the full oncology portfolio for additional treatment options.

Approved Indications for Baricinix 2MG & 4MG (Baricitinib)

Baricinix (Baricitinib) 2mg and 4mg is approved for the following clinical indications in adult patients:

Key Clinical Benefits of Baricinix (Baricitinib) 2mg and 4mg

How to Take Baricinix 2MG & 4MG (Baricitinib) Dosage Guidelines

Clinical Monitoring Requirements During Baricinix Treatment

Regular clinical monitoring is mandatory throughout Baricinix (Baricitinib) treatment. Healthcare providers must monitor for signs of serious bacterial, viral, fungal, and opportunistic infections, as Baricitinib suppresses JAK-STAT immune signalling and reduces immune surveillance capacity. Monitoring parameters include Complete Blood Count (CBC) for lymphopenia, neutropenia, and anaemia; liver function tests (LFTs); lipid panels including LDL and HDL cholesterol (Baricitinib may elevate both); renal function via serum creatinine and estimated GFR; and clinical assessment for signs of venous thromboembolism (VTE), malignancy, and major adverse cardiovascular events (MACE). Patients should report any fever, unusual fatigue, shortness of breath, or signs of infection to their physician without delay.

Drug Interactions and Important Safety Information for Baricinix

Concomitant use of Baricinix with other JAK inhibitors, biologic DMARDs (such as adalimumab, etanercept, or tocilizumab), or potent immunosuppressants including azathioprine and cyclosporine must be avoided. Combining these agents increases the risk of additive immunosuppression, serious infections, and lymphopenia without established clinical benefit.

The Baricinix dose must be reduced to 2mg once daily when co-administered with strong Organic Anion Transporter 3 (OAT3) inhibitors such as probenecid, because OAT3 inhibition increases Baricitinib plasma exposure by approximately 2-fold. Live vaccines must not be administered during Baricinix therapy or shortly before initiating treatment. Patients should inform their prescribing physician of all medications, supplements, and herbal products currently being taken before starting Baricinix.

Side Effects and Precautions of Baricinix (Baricitinib)

Who Should Use Baricinix 2MG & 4MG (Baricitinib)?

Baricinix is indicated for adult patients diagnosed with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more DMARDs; adult patients with moderate to severe atopic dermatitis not controlled by conventional systemic therapies; and adult patients with severe alopecia areata. Baricinix is prescribed by rheumatologists, dermatologists, and specialist physicians with experience in managing autoimmune and inflammatory conditions. A thorough pre-treatment medical assessment including complete blood count, renal function, liver function, lipid levels, and screening for latent tuberculosis and hepatitis B and C is required before initiating therapy. Patients with concurrent or historical malignancy should consult their oncologist; Mediaid Pharmacy’s oncology specialty medicines portfolio supports multidisciplinary management across autoimmune and oncology indications.

Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh

Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh and the number one oncology and specialty medicine company in the country. Beacon was the first company in Bangladesh to export cancer drugs and currently exports to markets across Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards. Baricinix (Baricitinib) 2mg and 4mg is one of Beacon’s internationally recognised specialty autoimmune products, offering a high-quality, bioequivalent, and affordable alternative to Olumiant by Eli Lilly at a fraction of the originator cost. Every batch exported by Beacon meets the quality benchmarks required for approval in regulated international markets.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Baricinix (Baricitinib)

Mediaid Pharmacy is a trusted global supplier of specialty, autoimmune, and oncology medications. Baricinix (Baricitinib) 2mg and 4mg is available through Mediaid Pharmacy with reliable worldwide shipping to South Asia, the Middle East, Africa, Europe, and beyond. Our team provides full order support including pricing, availability confirmation, documentation, and delivery tracking. Contact Mediaid Pharmacy directly via WhatsApp, phone, or WeChat for enquiries.

Why Choose Baricinix (Baricitinib) from Mediaid Pharmacy?

Baricinix represents a clinically proven advancement in the treatment of autoimmune and inflammatory conditions. As the generic bioequivalent of Olumiant by Eli Lilly and Incyte, Baricinix delivers the same active ingredient Baricitinib with the same proven JAK1 and JAK2 inhibition mechanism, at a dramatically more affordable price point. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy with worldwide shipping, Baricinix gives patients and healthcare providers access to high-quality advanced autoimmune therapy without the financial barrier of brand-name pricing. For patients whose treatment plans also require cancer medicines, Mediaid Pharmacy’s oncology medicines section provides a comprehensive range of specialty oncology products sourced from verified manufacturers. For any patient or physician seeking a proven, affordable, and globally accessible Baricitinib treatment option, Baricinix from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Baricinix 2MG & 4MG (Baricitinib)